PRIMEinvestor

Up $160,000 IN ONE DaY!!! Is this real life? Am I dreaming? Thank you $PRME $XBI

Why do I feel like it is a +10% day for $PRME

Last Thursday, Oppenheimer set an $11 price target for $PRME, projecting 200% upside over the next 10–15 months. The firm dismissed concerns over high short interest, stating it does not stem from the company's underlying fundamentals.

@blueskymindtq @GeneInvesting Thanks

@crisprspace @GeneInvesting Good for you . Might be the best strategy 👍

The number one thing I’m watching this year is the timetable from $PRME on CF. (Number 2 is Nex-z enrollment safety+speed) The moment that gets proven in vivo in humans, even for the smaller mutations, I can’t see how that’s not a $10b+ company (especially if WD and AATD also work next year). Even with dilution I’d be looking for ~$40/share. Considering next year is the earliest for IND-enabling, that means 2028 is the earliest for IND/into the clinic. If they can reach $10b MC, a 10% dilution could net them a cool $1b and that’s the type of money that really accelerates DISEASE ERADICATION (trademark pending 😉).

@blueskymindtq @GeneInvesting I am just trying not to time the market

@GeneInvesting @crisprspace Prime is the future ! But even the beginning of the smallest catalyst for Wilson's and CF only starts next year. 2027 will be the year

🧬 6 Gene Editing Facts $NTLA $PRME $BEAM $CRSP 1️⃣ Partial correction is enough for many diseases • You don’t need 100% editing • Duchenne Muscular Dystrophy: ~10–20% dystrophin matters • Cystic Fibrosis: minority of corrected cells can work 2️⃣ In vivo delivery outside the liver is coming • LNP + SORT + ligands + amino acid cocktails are all progressing 3️⃣ Repeat dosing has already been successful • Intellia has shown successful repeat dosing in the liver for ATTR and HAE • Even though they have no plans to use repeat dosing for these diseases, this info could play a major role moving forward when targeting hard to reach organs/tissues 👉 #1-3 can massively expand viable targets 4️⃣ One disease can make a company • See Vertex w/ CF or Alnylam with ATTR • We can see history repeating itself with Beam (SCD/AATD), Intellia (HAE/ATTR), and Prime with (AATD/CF) 5️⃣ATTR has HIGH unmet need • Transthyretin Amyloidosis drugs slow disease, they don’t reverse most damage • Nearly all patients continue worsening, it’s just a matter of how much • Silencers/Stabilizers ≠ cures → editing still has a huge role to play • Nex-z can be a functional cure for some patients (if given early enough) and that matters to patients 6️⃣ HAE has significant unmet need • thousands of patients still have breakthrough attacks • any throat attack could be life threatening • to patients there is a huge difference from 90% attack reduction and 100% • likely the first ever in-vivo CRISPR FDA approval and only ~1 year away

@Aureliu25819482 Let’s see :)

@crisprspace This is a monumental achievement. 195,000, wow. You will likely retire the next 5 generations in your family bro 👏🏻🙌🏻

Whaaaatt?? 195,951 shares of $PRME!!! My buying spree continues. That is how millions are made $XBI $NTLA

@GeneInvesting Finding the right partner is the most important thing in the world

@crisprspace Sounds like a keeper. Honestly I might need a therapist in the future because I can’t buy even close to as much as I want of that or NTLA

@GeneInvesting Honestly it is my wife that is buying these shares quite adamantly.

@crisprspace 200,000 even or don’t post again 😉

$PRME!!!

@drsessasarasota @GeneInvesting What????

@crisprspace @GeneInvesting Good company but do u really think politicians will allow farmers to be crushed with inflation - not gonna happen - this trade is falling apart quick

I silently built a $115,000 worth of $NTLA position over the course of three months. @GeneInvesting will be proud. Very undervalued stock. $PRME $XBI

Top 10 pharma companies by drug sales (in 2025), and how much comes from the top drug

@GeneInvesting They tested a guy that was bound to fail.

@crisprspace Why mad? I’ll tell you if you are mad for good reason or not haha

@GeneInvesting I am still mad at the company but the price is too compelling

@crisprspace Very sneaky to talk bad about it as you buy lol

It might be a good time for @GeneInvesting to promote my channel after my final $NTLA move :) I want to cross this 1000 member curse. Come on bro.

The only reason why I want to be very rich is because I want my children to have a care free life. Now they are able to take private swimming classes, acting classes and gym sessions because I made the right choices with my investments. I want that pattern to continue in the future. I live for my children. $PRME is the gateway to that life.

READ THIS THREAD NOW $NTLA $BEAM $PRME $CRSP 🤞 if this pans out CRISPR stocks will moon. This might be the delivery breakthrough we all have been praying for 🙏

Regulators introduce framework allowing individualized therapies such as gene editing or RNA drugs to be approved with smaller datasets when traditional trials are impossible which could speed access for ultra‑rare conditions & shift safety monitoring to post‑approval studies. fda.gov/news-events/pr…